TGFA and pulmonary fibrosis: Similarly, in the TGFα model used in the current study, in vivo treatment with barasertib either as a preventive or as a therapeutic strategy led to decreased fibroproliferation and myofibroblast accumulation in the pathogenesis of pulmonary fibrosis.